Dosing and administration
The recommended dose of SPEVIGO® is a dose of 900 mg (2 x 450 mg/7.5 mL vials) administered as an intravenous infusion.1
If flare symptoms persist, an additional 900 mg dose may be administered 1 week after the initial dose.1
Treatment with SPEVIGO® should be initiated by physicians experienced in the management of patients with inflammatory skin diseases.1
Please see the Product Monograph for complete information.
